Economic effects of aspergillosis management in high-risk patients

Managed Care Interface

Volumn 18, Issue 4, 2005, Pages 46-52

  Leather, Helen ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; PYRROLE; TRIAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; HIGH RISK PATIENT; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; MORTALITY; NEPHROTOXICITY; OUTPATIENT CARE; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SURVIVAL; VISUAL DISORDER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PYRIMIDINES; TRIAZOLES; UNITED STATES;

EID: 19644399359     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Pinner RW, Teutsch SM, Simonsen L, et al: Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-198.
2. McNeil MM, Nash SL, Hajjeh RA, et al: Trends in mortality due to invasive mycotic diseases in the United States. 1980-1997. Clin Infect Dis 2001;33:641-647.
3. Wingard JR: Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dix 2004;39(suppl 1)38-43.
4. Dixon S, McKeen E. Tabberer M, et al: Economic evaluations of treatments for systemic fungal infections. Pharmacoeconomics 2004;22:421-433.
5. Dasbach EJ, Davies GM, Teutsch SM: Burden of apergillosis-related hospitalizations in the United States. Clin Infect Dis 2000;31:1524-1528.
6. Healthcare Cost and Utilization Project. Nationwide Inpatient Sample Release 5, 7996. Rockville, MD, Agency for Healthcare Research and Quality. 1999.
7. Wilson LS, Reyes CM, Stolpman M, et al: The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34.
8. Prendergast MM, Tong KB: The economic impact of aspergillosis: Analysis of hospital expenditures and payer reimbursements. Presented at Infectious Diseases Society of America's 41st annual meeting. San Diego, October 9-12, 2003.
9. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: Systematic review of the literature, Clin Infect Dis 2001;32:358-366.
10. Stevens DA, Kan VL, Judson MA, et al: Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
11. Patterson TF, Kirkpatrick WR, White M, et al: Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. Medicine 2000;79:250-260.
12. Walsh TJ, Hiemenz JW, Anaissie E: Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996;10:365-400.
13. Diekema D, Pfaller MA: Reason for optimism. Infect Med 2003;20:396.
14. Bates DW, Su L, Chertow CM, et al: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001:32:686-693.
15. Harbarth S, Burke JP, Lloyd et al: Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002;35:e120-e127.
16. Johnson LB, Kauffman CA: Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
17. Herbrecht R, Denning DW, Patterson TF, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engt J Med 2002;347:408-415.
18. Lewis SS, Hill GL, Talamantez RC, et al: Financial impact of voriconazole (VCZ) use in a university teaching hospital. Presented at Infectious Diseases Society of America's 41st annual meeting. San Diego. October 9-12, 2003.
19. Voriconazole (VFEND) product information, in Physicians Desk Reference. Montvale. NJ, Medical Economics Co., 2004.
20. Lewis JS, Boucher HW, Lubowski T, et al: Economic advantage of voriconazole (VRC) for primary treatment of invasive aspergillosis compared to conventional amphotericin B (CAB). Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy's 43rd annual meeting. Chicago, September 14-17, 2003.
21. Guglielmo BJ, Chau LS, Inciardi Jm et al: Cost analysis of amphotericin-based versus azole-based therapy in neutropenic hemaiology/oncology patients. Presented at Inter-science Conference on Antimicrobial Agents and Chemotherapy's 43rd annual meeting. Chicago. September 14-17, 2003.